Celularity IncCELUEarnings & Financial Report
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
CELU Q3 FY2025 Key Financial Metrics
Revenue
$5.3M
Gross Profit
$1.4M
Operating Profit
$-12.9M
Net Profit
$-23.1M
Gross Margin
26.1%
Operating Margin
-244.1%
Net Margin
-436.7%
YoY Growth
-43.2%
EPS
$-0.88
Celularity Inc Q3 FY2025 Financial Summary
Celularity Inc reported revenue of $5.3M (down 43.2% YoY) for Q3 FY2025, with a net profit of $-23.1M (down 43.3% YoY) (-436.7% margin). Cost of goods sold was $3.9M, operating expenses totaled $14.3M.
Key Financial Metrics
| Total Revenue | $5.3M |
|---|---|
| Net Profit | $-23.1M |
| Gross Margin | 26.1% |
| Operating Margin | -244.1% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
Celularity Inc Q3 FY2025 revenue of $5.3M breaks down across 2 segments, led by License Royalty And Other at $2.9M (55.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| License Royalty And Other | $2.9M | 55.7% |
| Degenerative Disease | $2.2M | 42.5% |
Celularity Inc Revenue by Segment — Quarterly Trend
Celularity Inc revenue by segment across the last 4 reported quarters, showing how each business line (such as License Royalty And Other and Degenerative Disease) has evolved quarter over quarter.
| Segment | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 |
|---|---|---|---|---|
| License Royalty And Other | $2.9M | $2.1M | — | — |
| Degenerative Disease | $2.2M | $3.7M | $9.8M | $16.2M |
Celularity Inc Annual Revenue by Year
Celularity Inc annual revenue history includes year-by-year totals (for example, 2024 revenue was $54.2M).
Celularity Inc Quarterly Revenue & Net Profit History
Celularity Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $5.3M | -43.2% | $-23.1M | -436.7% |
| Q2 FY2025 | $5.7M | -52.6% | $-24.5M | -427.5% |
| Q1 FY2025 | $11.4M | -22.2% | $-19.8M | -172.9% |
| Q4 FY2024 | $18.1M | +49.7% | $-13.3M | -73.3% |
| Q3 FY2024 | $9.3M | +145.5% | $-16.1M | -173.2% |
| Q2 FY2024 | $12.1M | +312.2% | $-6.5M | -53.6% |
| Q1 FY2024 | $14.7M | +273.1% | $-22.0M | -149.9% |
| Q4 FY2023 | $12.1M | +193.3% | $9.5M | 78.8% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $14.7M | $12.1M | $9.3M | $18.1M | $11.4M | $5.7M | $5.3M |
| YoY Growth | 193.3% | 273.1% | 312.2% | 145.5% | 49.7% | -22.2% | -52.6% | -43.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $143.9M | $143.8M | $135.5M | $128.8M | $132.7M | $128.9M | $120.3M | $114.2M |
| Liabilities | $102.9M | $112.6M | $107.7M | $111.6M | $123.8M | $134.4M | $145.8M | $134.3M |
| Equity | $41.0M | $31.2M | $27.8M | $17.3M | $8.8M | $-5.5M | $-25.5M | $-20.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-4.3M | $-4.4M | $-3.4M | $-144000 | $1.6M | $-3.0M | $-999000 | $-4.2M |